190 related articles for article (PubMed ID: 32840426)
61. Causes of therapeutic errors in older adults: evaluation of National Poison Center data.
Hayes BD; Klein-Schwartz W; Gonzales LF
J Am Geriatr Soc; 2009 Apr; 57(4):653-8. PubMed ID: 19220563
[TBL] [Abstract][Full Text] [Related]
62. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States.
Wang GS; Roosevelt G; Le Lait MC; Martinez EM; Bucher-Bartelson B; Bronstein AC; Heard K
Ann Emerg Med; 2014 Jun; 63(6):684-9. PubMed ID: 24507243
[TBL] [Abstract][Full Text] [Related]
63. Understanding Cannabis-Based Therapeutics in Sports Medicine.
Maurer GE; Mathews NM; Schleich KT; Slayman TG; Marcussen BL
Sports Health; 2020; 12(6):540-546. PubMed ID: 32936058
[TBL] [Abstract][Full Text] [Related]
64. Illicit drug use and prescription drug misuse among young adult medical cannabis patients and non-patient users in Los Angeles.
Fedorova EV; Schrager SM; Robinson LF; Cepeda A; Wong CF; Iverson E; Lankenau SE
Drug Alcohol Depend; 2019 May; 198():21-27. PubMed ID: 30861391
[TBL] [Abstract][Full Text] [Related]
65. Poisoning in older adults: a 5-year experience of US poison control centers.
Crouch BI; Caravati EM; Mitchell A; Martin AC
Ann Pharmacother; 2004 Dec; 38(12):2005-11. PubMed ID: 15522976
[TBL] [Abstract][Full Text] [Related]
66. Trends in gabapentin and baclofen exposures reported to U.S. poison centers.
Reynolds K; Kaufman R; Korenoski A; Fennimore L; Shulman J; Lynch M
Clin Toxicol (Phila); 2020 Jul; 58(7):763-772. PubMed ID: 31786961
[No Abstract] [Full Text] [Related]
67. The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms.
Hazekamp A; Ware MA; Muller-Vahl KR; Abrams D; Grotenhermen F
J Psychoactive Drugs; 2013; 45(3):199-210. PubMed ID: 24175484
[TBL] [Abstract][Full Text] [Related]
68. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review.
Alves VL; Gonçalves JL; Aguiar J; Teixeira HM; Câmara JS
Crit Rev Toxicol; 2020 May; 50(5):359-382. PubMed ID: 32530350
[TBL] [Abstract][Full Text] [Related]
69. An outbreak of synthetic cannabinoid exposures reported to a regional poison center: "K2" identified as 5F-ADB.
Arens AM; Olives TD; Simpson NS; Laes JR; Anderson DL; Bangh SA; Lee SC; Martin S; Banister SD; Gerona RR; Cole JB
Clin Toxicol (Phila); 2019 Jan; 57(1):69-71. PubMed ID: 30430881
[No Abstract] [Full Text] [Related]
70. Cannabis legalization, tobacco prevention policies, and Cannabis use in E-cigarettes among youth.
Nicksic NE; Do EK; Barnes AJ
Drug Alcohol Depend; 2020 Jan; 206():107730. PubMed ID: 31759233
[TBL] [Abstract][Full Text] [Related]
71. The association between recreational cannabis commercialization and cannabis exposures reported to the US National Poison Data System.
Shi Y; Liang D
Addiction; 2020 Oct; 115(10):1890-1899. PubMed ID: 32080937
[TBL] [Abstract][Full Text] [Related]
72. Outcomes of acute exploratory pediatric lithium ingestions.
Minhaj FS; Anderson BD; King JD; Leonard JB
Clin Toxicol (Phila); 2020 Sep; 58(9):881-885. PubMed ID: 31913731
[No Abstract] [Full Text] [Related]
73. Relating calls to US poison centers for potential exposures to medications to Centers for Disease Control and Prevention reporting of influenza-like illness.
Beauchamp GA; McKeown NJ; Rodriguez S; Spyker DA
Clin Toxicol (Phila); 2016 Mar; 54(3):235-40. PubMed ID: 26818907
[TBL] [Abstract][Full Text] [Related]
74. Marijuana exposures in Colorado, reported to regional poison centre, 2000-2018.
Wang GS; Banerji S; Contreras AE; Hall KE
Inj Prev; 2020 Apr; 26(2):184-186. PubMed ID: 31676510
[TBL] [Abstract][Full Text] [Related]
75. Strokes are possible complications of cannabinoids use.
Wolff V; Jouanjus E
Epilepsy Behav; 2017 May; 70(Pt B):355-363. PubMed ID: 28237318
[TBL] [Abstract][Full Text] [Related]
76. Kratom exposures reported to United States poison control centers: 2011-2017.
Post S; Spiller HA; Chounthirath T; Smith GA
Clin Toxicol (Phila); 2019 Oct; 57(10):847-854. PubMed ID: 30786220
[No Abstract] [Full Text] [Related]
77. Cannabis and Cannabinoids for Chronic Pain.
Romero-Sandoval EA; Kolano AL; Alvarado-Vázquez PA
Curr Rheumatol Rep; 2017 Oct; 19(11):67. PubMed ID: 28983880
[TBL] [Abstract][Full Text] [Related]
78. Clinical and financial implications of emergency department visits for synthetic marijuana.
Rowley E; Benson D; Tiffee A; Hockensmith A; Zeng H; Jones GN; Musso MW
Am J Emerg Med; 2017 Oct; 35(10):1506-1509. PubMed ID: 28457767
[TBL] [Abstract][Full Text] [Related]
79. Medical cannabis: What practitioners need to know.
Van Rensburg R; Pillay-Fuentes Lorente V; Blockman M; Moodley K; Wilmshurst JM; Decloedt EH
S Afr Med J; 2020 Feb; 110(3):192-196. PubMed ID: 32657695
[TBL] [Abstract][Full Text] [Related]
80. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.
Orsolini L; Chiappini S; Volpe U; Berardis D; Latini R; Papanti GD; Corkery AJM
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
